KYBELLA® (deoxycholic acid) is the only FDA-approved injectable, for adults, that targets the unwanted fat beneath the chin! Deoxycholic acid is a naturally occurring molecule in the body, which is responsible for the breakdown and absorption of dietary fat. When injected into fatty tissue, KYBELLA® destroys fat cells, permanently!
After the skin is cleaned and prepped, the nurse assesses the area and marks out the perimeters, with a "skin pen". A "temporary tattoo" is applied to the skin, to indicate the injection pattern needed. KYBELLA® is a comes in individual vials, and is in clear liquid form. The solution is drawn up and injected, into the area, via multiple subcutaneous injections. The whole process takes approximately twenty minutes.
2. How many sessions does it take?
The amount needed, per session, can vary from client to client, and from session to session. On average, 2-3 vials are needed, for each session, and approximately 2-3 sessions total. It takes approximately 4-6 weeks before results can begin to be seen.
3. Is it painful?
While most individuals consider the KYBELLA® injections to be minimally uncomfortable, there can be a "burning" or "warm tingling" sensation felt, during treatment, as the product takes effect, in the fatty tissue. For most individuals, this sensation is brief and tolerable. Afterward, there can also be some tenderness to the treated area. Some of the experienced side effects associated with KYBELLA® include: swelling, bruising, numbness, redness, itching, and warmth.
4. What is the downtime?
As with every procedure, individual responses may vary. On average, swelling and tenderness can be present up to around three weeks after treatment, improving in severity each week, with the first week bringing the most noticeable of the expected side effects.
5. What is the cost?
KYBELLA® treatments are charged by the vial. Each vial is $600.00.
6. What about maintenance?
Since the fat cells are destroyed by this treatment, once the individual achieves the results desired, there are no anticipated follow up treatments.
7. What other areas can be treated?
Currently, only the submental ("double chin") area has been FDA-approved. Off-label uses include: inner thighs, "saddle-bag" areas, "love handles", the abdomen, fatty pockets between the breast and upper arm, "bra fat", and backs of arms.
Client above shown (left) prior to KYBELLA® treatment and (right) 4 weeks after.
KYBELLA® Professional ISI Indication KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended. Important Safety Information Contraindications KYBELLA® is contraindicated in the presence of infection at the injection sites. Warnings and Precautions Marginal Mandibular Nerve Injury Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. Dysphagia Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition. Injection-Site Hematoma/Bruising In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur. Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Adverse Reactions The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration. Please see KYBELLA® full prescribing information.